Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients-Reference-Cited by-同舟云学术

Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients

Published:2019-10-16 Issue:2 Volume:20 Page:202-212
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Cusato Jessica,Calcagno Andrea^ORCID,Marinaro Letizia,Avataneo Valeria,DʹAvolio Antonio,Di Perri Giovanni,Bonora Stefano

Funder

A.C. has received grants from Gilead and Bristol-Myers Squibb (BMS), travel grants and speaker's honoraria from Abbvie, BMS, Merck Sharp & Dohme (MSD), Gilead, Janssen-Cilag, and Viiv.

G.D.P. has received grants, travel grants and consultancy fees from Abbvie, Boehringer-Inghelheim, BMS, MSD, Gilead, Janssen-Cilag, and Viiv.

S.B. has received grants, travel grants and consultancy fees from Abbvie, Boehringer-Inghelheim, BMS, MSD, Gilead, Janssen-Cilag, and Viiv.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

http://www.nature.com/articles/s41397-019-0109-x.pdf

Reference51 articles.

1. Hogg RS, Eyawo O, Collins AB, Zhang W, Jabbari S, Hull MW, et al. Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study. Lancet HIV. 2017;4:e270–6.

2. Gallant JE, Pham PA. Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection. Expert Rev Anti Infect Ther. 2003;1:415–22.

3. Calcagno A, Di Perri G, Bonora S. What do we know about tailoring treatment with tenofovir? Pharmacogenomics. 2016;17:531–4.

4. Dahlin A, Wittwer M, de la Cruz M, Woo JM, Bam R, Scharen-Guivel V, et al. A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. Pharmacogenet Genomics. 2015;25:82–92.

5. Hemkens LG, Ewald H, Santini-Oliveira M, Buhler JE, Vuichard D, Schandelmaier S, et al. Comparative effectiveness of tenofovir in treatment-naive HIV-infected patients: systematic review and meta-analysis. HIV Clin Trials. 2015;16:178–89.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenetics of tenofovir drug transporters in the context of HBV: Is there an impact?;Biomedicine & Pharmacotherapy;2024-06

2. Pharmacogenetic effects of single nucleotide polymorphisms commonly associated with antiretroviral therapy metabolism;HIV Infection and Immunosuppressive Disorders;2022-11-10

3. Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs;Expert Opinion on Drug Metabolism & Toxicology;2022-08-03

4. Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study;AIDS Research and Therapy;2021-05-27

5. Brief Report: CYP27B1 rs10877012 T Allele Was Linked to Non-AIDS Progression in ART-Naïve HIV-Infected Patients: A Retrospective Study;JAIDS Journal of Acquired Immune Deficiency Syndromes;2020-12-15